AliMed, Inc. Awarded Pediatric Straps and Positioners Agreement with Premier, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, has been awarded a national group purchasing agreement for pediatric straps and positioners with Premier, Inc., and their Performance Group, Kiindo™.

Effective June 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for pediatric straps and positioners.

“AliMed is committed to serving the pediatric community with high-quality healthcare products designed specifically for their needs,” said Adrienne Hamilton, Director of Marketing at AliMed. “We are excited about this agreement and look forward to working with Premier members to help them realize cost savings, improve efficiencies, and support better quality outcomes across the pediatric continuum of care.”

Alimed, Inc. Awarded Pediatric Straps And Positioners Agreement With Premier, Inc.
The AliMed-Premier Kiindo contract agreement includes a wide range of pediatric patient straps and surgical and rehab positioners tailored to the unique needs of children.

With many products tailored to the unique needs of children from neonatal to adolescents, the AliMed contract includes imaging and surgical straps that provide support and stabilization without damaging delicate pediatric skin, surgical positioners appropriately sized to help relieve pressure from head to foot during procedures, and rehab positioners that aid with strengthening motor skills, balance, mobility, feeding, and more.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”